Lista de obras - Camilla Qvortrup - Dominio Público Uruguay

A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.

artículo científico publicado en 2015

Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.

artículo científico publicado en 2010

Adjuvant chemotherapy for patients with rectal cancer

artículo científico publicado en 2013

Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer.

artículo científico publicado en 2013

Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer

artículo científico publicado en 2011

Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example

artículo científico publicado en 2016

Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies

scientific article published on 25 January 2014

Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives.

artículo científico publicado en 2015

Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.

artículo científico publicado en 2008

Current role of antibody therapy in patients with metastatic colorectal cancer.

artículo científico publicado en 2007

Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients.

artículo científico publicado en 2009

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

artículo científico publicado en 2010

Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.

artículo científico publicado en 2016

Global cancer control: responding to the growing burden, rising costs and inequalities in access.

artículo científico publicado en 2018

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer.

artículo científico publicado en 2017

High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.

artículo científico publicado en 2013

How to overcome resistance to therapy?

artículo científico publicado en 2012

Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study.

artículo científico publicado en 2009

Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC).

artículo científico publicado en 2008

Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone ⬇️

artículo científico publicado el 10 de mayo de 2012

Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group.

artículo científico publicado en 2015

Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer

scientific article published on 19 July 2010

Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey.

artículo científico publicado en 2017

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.

artículo científico publicado en 2017

Review on adjuvant chemotherapy for rectal cancer - why do treatment guidelines differ so much?

artículo científico publicado en 2015

S-1 in combination with docetaxel and oxaliplatin in patients with advanced gastro-esophageal adenocarcinoma: two parallel phase 1/2a studies

artículo científico publicado en 2016

Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer

artículo científico publicado en 2016

The Pocketable Electronic Devices in Radiation Oncology (PEDRO) Project: How the Use of Tools in Medical Decision Making is Changing?

artículo científico publicado en 2015

Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.

artículo científico publicado en 2014

Trends in colorectal cancer in the elderly in Denmark, 1980-2012.

artículo científico publicado en 2016

[Tailored treatment to patients with metastatic colorectal cancer]

artículo científico publicado en 2009

Lista de obras de Camilla Qvortrup

A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.

Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.

Adjuvant chemotherapy for patients with rectal cancer

Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer.

Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer

Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example

Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies

Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives.

Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.

Current role of antibody therapy in patients with metastatic colorectal cancer.

Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.

Global cancer control: responding to the growing burden, rising costs and inequalities in access.

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer.

High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.

How to overcome resistance to therapy?

Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study.

Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC).

Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone ⬇️

Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group.

Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer

Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey.

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.

Review on adjuvant chemotherapy for rectal cancer - why do treatment guidelines differ so much?

S-1 in combination with docetaxel and oxaliplatin in patients with advanced gastro-esophageal adenocarcinoma: two parallel phase 1/2a studies

Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer

The Pocketable Electronic Devices in Radiation Oncology (PEDRO) Project: How the Use of Tools in Medical Decision Making is Changing?

Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.

Trends in colorectal cancer in the elderly in Denmark, 1980-2012.

[Tailored treatment to patients with metastatic colorectal cancer]